Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boston Scientific Corporation
The purpose of this prospective, randomized multi-center clinical study is to establish the benefits of the CryoCor(TM) Cardiac Cryoablation System for treating symptomatic paroxysmal atrial fibrillation (PAF) in comparison to treatment with anti-arrhythmic medications alone. This study also evaluates the safety profile of the CryoCor(TM) Cardiac Cryoablation System when used in this same setting.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least 3 episodes of PAF within 6 months
Refractory to at least one drug
Therapeutic anticoagulation
Signed informed consent
You may not be if
Persistent AF
Structural heart disease
Prior ablation
Contraindication present
Clareo Health | Safety and Efficacy of CryoCor™ Cryoablation for PAF
